LIVN - LivaNova PLC
| Previous Close | 94.45 |
| Open | 93.86 |
| Bid | 91.00 x 1100 |
| Ask | 199,999.98 x 1100 |
| Day's Range | 90.66 - 93.86 |
| 52 Week Range | 76.14 - 131.54 |
| Volume | 554,203 |
| Avg. Volume | 557,980 |
| Market Cap | 4.448B |
| Beta (3Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 129.43 |
Markit•5 days agoSee what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVN
- Insider Monkey•8 days ago
LivaNova PLC (LIVN)Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
Markit•14 days agoSee what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVN
- GlobeNewswire•19 days ago
Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•22 days ago
LivaNova Partners with Greg Grunberg to Raise Epilepsy Awareness
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it has joined forces with actor and epilepsy advocate Greg Grunberg. The partnership kicked off at the Epilepsy Awareness Day at Disneyland Education Expo, where Grunberg joined LivaNova to raise awareness of seizures, drug-resistant epilepsy (DRE) and the available treatment options.
Markit•24 days agoSee what the IHS Markit Score report has to say about LivaNova PLC.
Short interest is extremely low for LIVN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LIVN. ETFs that hold LIVN had net inflows of $2.03 billion over the last one-month.
- Motley Fool•28 days ago
Why L Brands, Devon Energy, and LivaNova Slumped Today
Corporate struggles, falling oil prices, and regulatory speedbumps weighed on these stocks.
- Motley Fool•28 days ago
Here's Why LivaNova Dropped Today
The Centers for Medicare and Medicaid Services wants some more data before covering the company’s depression therapy.
- Business Wire•28 days ago
LivaNova Comments on Proposed Decision Memo from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (LIVN), a market-leading medical technology company, today commented on the U.S. Centers for Medicare & Medicaid Services (CMS) Proposed Decision Memo regarding its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for Treatment-Resistant Depression (TRD). Within the Proposed Decision Memo, CMS proposes to change the NCD for VNS Therapy for TRD to expand Medicare coverage.
- Business Wire•29 days ago
LivaNova to Present at the Piper Jaffray and Berenberg Conferences
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions during the Piper Jaffray 30th Annual Healthcare Conference in New York and at the Berenberg European Conference 2018 in London. The discussion at the Piper Jaffray conference is scheduled to begin at 11 a.m. Eastern Time on Wednesday, Nov. 28, and the discussion at the Berenberg conference is scheduled to begin at 4 p.m. Greenwich Mean Time on Wednesday, Dec. 5. The Piper Jaffray discussion will be available to all interested parties through a live audiocast accessible via the Investor Relations section of LivaNova's website at www.livanova.com.
Markit•last monthSee what the IHS Markit Score report has to say about LivaNova PLC.
Short interest is extremely low for LIVN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LIVN. ETFs that hold LIVN had net inflows of $2.12 billion over the last one-month.
Motley Fool•2 months agoLivaNova PLC (LIVN) Q3 2018 Earnings Conference Call Transcript
LIVN earnings call for the period ending September 30, 2018.
- Zacks•2 months ago
LivaNova (LIVN) Misses Q3 Earnings and Revenue Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of -10.34% and -0.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•2 months ago
LivaNova Reports Third Quarter 2018 Results
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018.
- Zacks•2 months ago
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
- Business Wire•2 months ago
LivaNova to Present at the Stifel 2018 Healthcare Conference
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
- GlobeNewswire•2 months ago
Recent Analysis Shows Crestwood Equity Partners LP, The Goldman Sachs Group, Lam Research, RYB Education, Inc. Sponsored ADR, Ecolab, and LivaNova Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Markit•2 months agoSee what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVN
- Business Wire•3 months ago
LivaNova to Host Conference Call for Third Quarter 2018 Results
LivaNova PLC (LIVN), a market-leading medical technology company, will host a conference call to discuss its third quarter 2018 results on Wednesday, Oct. 31, 2018 at 12 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its third quarter 2018 results prior to the call.
Markit•3 months agoSee what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVN
- Business Wire•3 months ago
LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure
LivaNova PLC (LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA® System in a patient enrolled in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study. The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the treatment of advanced heart failure. The first implant in the pivotal study was completed at UnityPoint Health – St. Luke’s Hospital in Cedar Rapids, Iowa, by Dr. Jared Kray.
- Business Wire•3 months ago
LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement
LivaNova PLC (LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for sutureless aortic valve replacement issued by the U.K. National Institute for Health and Care Excellence (NICE), which states that sutureless aortic valve replacement is an alternative to conventional surgical aortic valve replacement. The NICE guidance comes as LivaNova completes enrollment for a global aortic valve replacement clinical trial comparing the benefits of sutureless versus standard aortic valve replacement for aortic stenosis.
- Business Wire•3 months ago
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that a new cost analysis found the Company’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System results in lower resource utilization and lower cost for drug-resistant epilepsy (DRE) patients when compared to continued treatment with anti-epileptic drugs (AEDs).1 The analysis, published in Advances in Therapy and supported by LivaNova, showed initial costs for the VNS Therapy device, including placement and programming, were estimated to be offset 1.7 years post-implant and equated to an estimated net cost savings of $77,480 per patient over five years. The net cost savings are due primarily to a reduction in seizure-related hospitalizations, resulting in a 21.5 percent decrease in costs compared to treatment with AEDs alone.
- Business Wire•4 months ago
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients
LivaNova PLC (LIVN), a market-leading medical technology company, today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy (DRE), which affects nearly one in three people with epilepsy.1 The Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with VNS Therapy (CORE-VNS) study will enroll up to 2,000 patients with five-year follow-up data, yielding one of the largest data sets in the world for DRE patients treated with various generations of VNS Therapy. Data from CORE-VNS will contribute to the body of research related to this disease state and advance the science behind VNS Therapy by evaluating the safety, effectiveness and clinical outcomes for patients.
- Business Wire•4 months ago
LivaNova to Present at Morgan Stanley Global Healthcare Conference
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer of LivaNova, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, Sept. 13 in New York at 10 a.m. Eastern Daylight Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
